Design Therapeutics (NASDAQ:DSGN) Releases Earnings Results, Beats Expectations By $0.02 EPS

Design Therapeutics (NASDAQ:DSGN) posted its quarterly earnings data on Monday. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.02, Yahoo Finance reports.

Design Therapeutics Stock Down 9.7 %

DSGN stock opened at $4.21 on Wednesday. Design Therapeutics has a twelve month low of $1.94 and a twelve month high of $7.83. The company has a market cap of $237.84 million, a P/E ratio of -4.01 and a beta of 1.83. The business’s fifty day moving average is $3.99 and its 200-day moving average is $3.55.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on DSGN. Piper Sandler upgraded Design Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $6.00 to $12.00 in a research report on Tuesday, May 7th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $4.00 price objective on shares of Design Therapeutics in a research report on Tuesday. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, Design Therapeutics presently has an average rating of “Hold” and an average price target of $6.60.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.